ideasIdea
A mandatory patient-experience section in every cancer drug label and approval
The official information about a new cancer drug must include what patients on the trial actually reported about side-effects and daily life, not only survival curves.
The FDA Oncology Center of Excellence's Project Patient Voice began publishing patient-reported symptom data from trials, but labels remain silent on patient-reported outcomes for most drugs. The proposal is a required, standardised patient-experience section (PRO-CTCAE symptom frequency, physical function trajectory, time toxicity) in every oncology label and public assessment report, and a voting patient member on advisory committees with access to the same data.
Hypothesis
Labels with patient-experience sections change prescribing towards better-tolerated regimens when efficacy is similar and increase sponsors' collection of high-quality PRO data in registrational trials.
Rationale
Sponsors collect what regulators read. Making patient experience a labelled claim gives it commercial value and standardises how it is measured.
What would test it
Regulator pilots the section for all approvals over two years; survey prescribers and measure uptake of PRO instruments in subsequent pivotal protocols.
Maturity
early clinical
Who has to act
regulator
Cost to try
Small (under $1M)
Years to first evidence
3
Bottlenecks it attacks
- Patients lack understanding, navigation and agency · Most patients cannot understand their options, find trials, or push back, so decisions are made for them.
- Regulatory divergence between regions · Regulatory divergence means a drug approved in one country can take years to reach another, or never arrive.